IN THE MATTER OF	*	BEFORE THE
BEHROOZ GOODARZI, P.D.	*	MARYLAND STATE
LICENSE NO. 10724	*	BOARD OF PHARMACY
RESPONDENT	*	

* *

ORDER FOR SUMMARY SUSPENSION OF PHARMACIST'S LICENSE

Background

On April 6, 1999, the Maryland State Board of Pharmacy (the "Board") issued a notice of intent to summarily suspend the pharmacist' license held by Behrooz Goodarzi, P.D., License No. 10724 (the "Respondent"). The Respondent was given an opportunity for a hearing to show cause as to why the Board should not issue an unexecuted order that would have suspended his pharmacist's license due to the imminent threat to the public health created by dangerous practices at the pharmacy. (See the Board' unexecuted order attached as Exhibit #1 hereto and incorporated by reference herein). A show cause hearing before a panel of the Board was held on April 13, 1999. This show cause hearing was limited to oral argument, direct examination of the Respondent, and an examination of the inventory prepared by the Division of Drug Control inspector, C. Putz, based upon her observations of the Pharmacy on March 24, 1999 and March 30, 1999.

FINDINGS OF FACT BASED ON PROBABLE CAUSE

Based upon the investigation and the show cause hearing, the Board has reason to believe there exists probable cause that the following facts are true:

1. At all times relevant, the Respondent was licensed as a pharmacist in the State of Maryland.

2. At all times relevant, the Respondent operated a pharmacy known as Melwood Pharmacy

at 9644 Marlboro Pike, Upper Marlboro, Maryland 20072 (the "Pharmacy").

3. Acting on a complaint that expired drugs had been dispensed at the Pharmacy, the Division of Drug Control performed an inspection on March 24, 1999, at the Melwood Pharmacy. A follow-up inspection was performed on March 30, 1999.

4. Upon inspection, the following was found:

a) Liquid medications were stored in soda bottles;

b) There were numerous products without lot number or expiration dates.

c) There were over 525 outdated products;

d) The Respondent was not aware that he should destroy outdated CDS, and DEA form 41 was provided to him;

e) There were expiration dates and lot numbers covered by the price stickers;

f) Loose pills were found on the shelves;

g) The outdated products date as far back as 1987.

5. The following is a list of outdated products by category[1], found at the Pharmacy on March 24 through 30, 1999: electrolyte supplements, anti-psychotics, anti-hypertensive, antibiotics, antitussives, antihistamines, acid blockers, circulation medications, Antibuse, pain relievers, Alzheimer management medications, tranquilizers, diuretics, prenatal vitamins, medications for the control of obsessive compulsive disorders, anti-inflammatory creams, steroidals, antigout products, acne lotion, saliva substitute, progesterone, antibiotic acne liquid, aspirin/codeine products,

---

[1] Attached as part of Exhibit # 1 and incorporated by reference herein is the inventory of March 24, 1999, and March 30, 1999, prepared by C. Putz of the Division of Drug Control and signed by Respondent.

antivirals, calcium channel blockers, pain relievers, expectorants, enemas, anti-inflammatory medications, sleep aids, pediculacide, UTI medications, vitamins, urinary antiseptics, antinausea, anti-ulcer, mobility agents, anticoagulants, thyroid supplements, anti-depressants, muscle relaxants, tuberculosis drugs, antiarrhythmic heart medications, antidiabetics, asthma medications, oral contraceptives, ear anti-infectives, potassium supplements, anti-miasthenics, antiseizure products, bulk hormones for compounding, laxatives, Schedule III[2] cough suppressant/expectorants, Schedule III pain relievers, Schedule IV tranquilizers, and Doral, a Schedule IV sedative. In addition to the above, these categories of pediatric specific medications were found: expectorant/decongestants, numerous antibiotics, cough/cold preparations, asthma and pain relievers. A bottle of Diethylstilbesterol, with an expiration date of May, 1994 was also found on the shelf of the Pharmacy. Diethylstibesterol is no longer on the market.

6. At the show cause hearing the Respondent defended his practice of putting liquid medications such as Zyrtec syrup into soda bottles despite the risk of contamination. His continued insistence in defense of this practice demonstrates incompetence and disregard for the public health and safety.

7. At the show cause hearing the Respondent claimed that he never had a chance to get rid of the outdated drugs and admitted that he had no system to flag outdated drugs. At the hearing he claimed that he has changed his practices since the inspection so that on each day he now pulls all outdated drugs off the shelves. He further stated that he now keeps his containers upside down when they are drawing near to the expiration date.

---

[2] Some of the products previously listed are scheduled drugs.

8. At the show cause hearing the Respondent claimed there were only 362 bottles of outdated products rather than 525. He admitted that "maybe" some of these outdated products had been on the shelf. The Board finds that it is most likely that many of these bottles were on the shelves and contained outdated drugs as reported by the inspector. Furthermore, there is absolutely no legitimate reason to have these quantities of outdated products in the store. Outdated pharmaceutical products can cause substantial harm to patients and the Board finds that there was no valid reason to possess these products in such numerous quantities and for such long periods of time. To possess these numerous quantities of outdated pharmaceutical products either shows extreme incompetence or an intent to dispense these outdated products. In either event, emergency action is required to protect the public.[3]

9. Because the Respondent is practicing pharmacy in an incompetent manner that exposes the public to the grave dangers of outdated, mislabeled, and contaminated drugs, the Board finds that emergency action is necessary to protect the public health, safety, and welfare.

CONCLUSIONS OF LAW

Based upon the foregoing Findings of Fact Based on Probable Cause, the Board finds that the public health, safety and welfare imperatively requires emergency action pursuant to Md. Code Ann., State Gov't Art., § 10-226(c)(1).

---

[3] The Board is especially troubled by the presence of such outdated products as pediatric medications, antibiotics, anti-hypertensives, antiarrhythmic heart medications, anti-psychotics, antivirals, progesterone, oral contraceptives, thyroid supplements, tuberculosis drugs, and medications used to control obsessive-compulsive disorders.

ORDER

Based upon the foregoing Findings of Fact Based on Probable Cause. it is this ___ day of _____, 1999. by a majority of the quorum of the Board. hereby

ORDERED that the Respondent's pharmacist's license be summarily suspended pursuant to Md. Code Ann.. State Gov't Art.. §10-226(c). And be it further

ORDERED that this a **FINAL ORDER** and as such is a public document pursuant to § 10-611 *et seq.* of the State Government Article. Annotated Code of Maryland. And be it further

ORDERED that this Order for Summary Suspension of Pharmacist's License and the same is hereby effective on the day it is signed. And be it further

ORDERED that the Respondent shall submit the display and renewal certificates issued for license no. 10724 to the Board's offices.

4/21/99
Date

W. Irving Lottier
W. Irving Lottier. Jr. P.D.
Secretary. Board of Pharmacy

IN THE MATTER OF	*	BEFORE THE
BEHROOZ GOODARZI, P.D.	*	MARYLAND STATE
LICENSE NO. 10724	*	BOARD OF PHARMACY
RESPONDENT	*	

* *

BOARD'S RULING ON RESPONSE
TO CHARGES AND MOTION TO DISMISS

For the reasons set forth below, the Board denies the Respondent's Motion to Dismiss Summary Suspension Hearing.

The Board does not need to address the Respondent's claims regarding the fact that he failed to possess a copy of the CDS Biennial Inventory and that he failed to record the names of generic manufacturer on prescriptions because the Board does not believe that these potential violations rise to the level of an imminent threat to the public health and safety. For the same reasons, the Board will not address the Respondent's claims regarding the plastic bag of controlled dangerous substances or the presence of sample drugs in the Pharmacy. The Board notes, however, that the Respondent should have kept a copy of the Biennial Inventory even if a copy of that Biennial Inventory had previously been requested by the Division of Drug Control as he claims.

At the show cause hearing and in his motion to dismiss, the Respondent disputed the amount of outdated products in his pharmacy, claiming that there were **only** 362, not 525, and claiming that the products on the pharmacy were empty and only used as reference points for organization purposes. He further claimed that most of the outdated drugs were stored separately in a box on the bottom of the pharmacy shelves. However, when questioned at the show cause hearing, he also admitted that "maybe" some of these outdated products were on the shelf. He insisted he did not use

these outdated products but that he "never had a chance to get rid" of them. He also admitted that he had no system to flag outdated products. In his motion to dismiss, the Respondent admits that some of the outdated products may have dated back as far as 1987.

The Board finds it completely unbelievable that the Respondent would keep this many outdated products for years without intending to dispense them to customers. The Board, in the exercise of its professional expertise finds that there is absolutely no legitimate reason under even minimal standards of pharmacy care for the Respondent to keep this many outdated prescription products in the pharmacy for such extended periods of time. Thus, the Respondent is either incompetent in the removal and disposal of outdated pharmaceuticals or he has been dispensing these outdated pharmaceuticals to patients. In either event, the Board, in the exercise of its professional expertise, finds that the public health is threatened by the Respondent's continued practice of pharmacy and emergency action is necessary to protect the public health and safety.

.In his motion to dismiss, the Respondent stated his belief that the inspectors' listing of outdated products is not accurate, which outdated products have been placed under seal and detained by the Division of Drug Control under authority of the Food, Drug and Cosmetic Act, Md. Code Ann., Health-General Art., §21-253, regarding the detainment of suspected adulterated or misbranded drugs. The Board believes that it is more likely than not that the inspectors of the Division of Drug Control would list the outdated pharmaceutical products accurately and would only detain them if they were in an adulterated condition such as being outdated. See Health-General Art., §21-216(b) (1) ("A drug or device is adulterated if any part of it is a filthy, putrid or decomposed substance."). Given that the Respondent has also admitted to the presence of 362 outdated pharmaceutical products, the Board finds that there is probable cause to believe that at least

this quantity of products were outdated.

In his motion to dismiss, the Respondent also admitted to having several small containers with price stickers covering the expiration dates and lot numbers, though he claimed they were easily removable. The Board find this practice to be simply unacceptable

The Respondent also splits hairs by offering a tortured definition of "pill" in a desperate effort to rebut the inspector's simple observation that loose pills were found on the Respondent's shelf. The Board believes that is likely that the inspector saw loose pills or tablets or capsules on the Respondent's shelf, the exact terminology used being wholly irrelevant to the controlling issue of whether the Respondent takes care to prevent contamination of his pharmaceutical products. The Respondent's vigorous defense of his unsanitary practice of the use of soda bottles to store liquid medications shows that his credibility must be seriously questioned regarding such matters.

Finally, in his motion to dismiss the Respondent claims that his due process rights have been violated because he claims he was not given fair notice of the statutes and regulations he is accused of violating. This argument ignores the fact that the Board's unexecuted summary suspension order set forth in detail the alleged facts and cited the controlling statutes. These alleged facts raised issues of incompetence and an imminent threat to the public health. The statutes that authorize the Board's summary suspension of the Respondent's license in response to such facts were cited in the unexecuted order, namely Md. Code Ann., State Gov't Art., §10-226(c) (stating that a licensing unit may order summarily the suspension of a license if the unit finds that the public health, safety, or welfare imperatively requires emergency action), and Md. Code Ann., Health Occ. Art., §12-313(20) (stating that a pharmacist may be disciplined if he is professionally, physically, or mentally incompetent).

The process given in this case was appropriate given the potential threat to the public health and the consequent need for quick action by the Board to protect the public health. "As has often been stated, '[d]ue process does not require adherence to any particular procedure. On the contrary, due process is flexible and calls for such procedural protections as the particular situation demands.'" *Maryland Racing Commission v. Castrenze*, 335 Md. 284, 299 (1994) (citations omitted here). The *Castrenze* upheld the summary suspension of a license prior to giving the licensee an opportunity to be heard. An important factor for the *Castrenze* court was the scope of the issues to be resolved at the hearing. *Id.*, 335 Md. at 300. The scope of the issues here was limited to whether the observations recorded in the Division of Drug Control inspection report constituted probable cause that the public health, safety, and welfare imperatively required emergency action. That issue was clearly stated in the original written notice to the Respondent. Thus, he was notified as to the relevant factual and legal issues so that he could prepare a defense.

The *Castrenze* court also held that another important factor to consider is the balancing of the government's interest against the licensee's interest. *Id.*, 335 Md. At 300. In this case, the Board's interest in avoiding delay in protecting the health and welfare of Maryland's citizens clearly outweighs the Respondent's more limited property interest in avoiding the erroneous deprivation of his pharmacist's license. *See Varandani v. Bowen,* 824 F.2d. 307, 310 (4th Cir. 1987) ("the courts have refused to require anything more than an informal hearing before a doctor is suspended from Medicare reimbursement in large part because of the interest of Medicare patients in not being treated by a doctor found by his peers to have engaged in grossly substandard practice."). *See also*, *Waltz v. Herlily*, 682 F.Supp. 501 (state may summarily suspend physician's license provided that adequate post-deprivation remedies are available); *Morton v. Beyer*, 822 F.2d. 364, 369, n. 11 (public

employee who poses a significant hazard is not constitutionally entitled to any kind of hearing). Thus, under these cases, the Respondent was given more process than is due under principles of constitutional law.

In addition, the Respondent was given more process than is required under Md. Code Ann., State Gov't Art. §10-226(c). Under that section, the Board could have suspended the license and then provided him with the reasons for the suspension afterwards. Instead, the Board chose to give the Respondent a pre-deprivation hearing and provided him with advance notice prior to taking action against his license.

For all the foregoing reasons, the Respondent's motion to dismiss is denied.

4/21/99
Date

W. Irving Lottier, Jr., P.D.
Secretary, Board of Pharmacy



IN THE MATTER OF	*	**BEFORE THE**
BEHROOZ GOODARZI, P.D.	*	**MARYLAND STATE**
LICENSE NO. 10724,	*	**BOARD OF PHARMACY**
RESPONDENT	*	

* *

ORDER FOR SUMMARY SUSPENSION OF LICENSE TO PRACTICE PHARMACY

Pursuant to Md. Code Ann., State Gov't, § 10-226 (c) (2) (1995), the Maryland State Pharmacy Board (the "Board") hereby suspends the license to practice pharmacy previously issued to **Behrooz Goodarzi, P.D.,** (the "Respondent"), License No. 10724, under the Maryland Pharmacy Act, Md. Code Ann., Health Occ. §12-101 et seq. (1994) (the "Act"). This Order is based on the following information, which the Board has reason to believe is true:

BACKGROUND

1. At all times relevant, Respondent was licensed to practice pharmacy in the State of Maryland. Respondent was initially licensed April 16, 1986.

2. The Division of Drug Control performed an inspection on March 24, 1999, at the Melwood Pharmacy located at 9644 Marlboro Pike, Upper Marlboro, Md. 20072. Respondent is the pharmacist owner of Melwood Pharmacy. A follow-up inspection was performed on March 30, 1999.

3. Upon inspection the following was noticed:

a) Respondent did not have the required CDS biennial inventory available;

b) the generic manufacturer was not recorded on the prescriptions;

c) the Schedule II drugs were found in a plastic bag on the floor of the pharmacy;

d) there were numerous misbranded products without lot number or expiration dates;

e) there were Sample drugs in violation of 21 U.S.C. 353 (c);

f) liquid medications were stored in soda bottles;

g) there were over 525 outdated products, as more fully described below;

h) Respondent was not aware that he should destroy outdated CDS, and DEA form 41 was provided to him;

i) expiration dates and lot numbers were being covered by the price stickers.

4) The following is a list of outdated products by category[1], found in Respondent's pharmacy on March 24 through 30, 1999: electrolyte supplements, antipsychotics, anti-hypertensive, antibiotics, antitussives, antihistamines, acid blockers, circulation medications, Antibuse, pain relievers, Alzheimer management medications, tranquilizers, diuretics, prenatal vitamins, medications for the control of obsessive compulsive disorders, anti-inflammatory creams, steroidals, antigout products, acne lotion, saliva substitute, progesterone, antibiotic acne liquid, aspirin/codeine products, antivirals, calcium channel blockers, pain relievers, expectorants, enemas, anti-inflammatory medications, sleep aids, pediculacide, UTI medications, vitamins, urinary antiseptics, antinausea, anti-ulcer, motility agents, anticoagulants, thyroid supplements, anti-depressants, muscle relaxants, tuberculosis drugs, antiarrhythmic heart medications, antidiabetics, asthma medications, oral contraceptives, ear anti-infectives, potassium supplements, anti-miasthenics, antiseizure products, bulk hormones for compounding, laxatives, Schedule III[2] cough suppressant/expectorants, Schedule III pain relievers, Schedule IV tranquilizers, and Doral

---

[1] Attached and incorporated hereto is the inventory of March 24, 1999, and March 30, 1999, prepared by C. Putz of the Division of Drug Control and signed by Respondent.

[2] Some of the products previously listed are scheduled drugs.

a Schedule IV sedative. In addition to the above, these categories of pediatric specific medications were found: expectorant/decongestants, numerous antibiotics, cough/cold preparations, asthma, and pain relievers. A bottle of diethylstilbesterol, with an expiration date of May, 1994 was also found on the shelf of Respondent's pharmacy.

5) Loose pills were also found on Respondent's shelves.

6) The expired products found in Respondent's pharmacy dated back as far as 1987.

7) Respondent's presence of a great amount of pharmaceutical inventory dating back twelve years, his presence of misbranded product, and his lack of proper storage of controlled dangerous substances are evidence that Respondent's practice of pharmacy is incompetent and is therefore contrary to the public health, safety and welfare.

CONCLUSIONS OF LAW

Based upon the foregoing, the Board finds that the public health, safety and welfare imperatively requires emergency action pursuant to Md. Code Ann., State Gov't §10-226 (c) (2) (1995). The Board finds that Respondent's conduct violates §§ 12-313 (b) (7) (willfully fails to file or record any report that is required by law), (16) (violates any provision of § 12-509 of this title, which concerns the labelling requirements for prescription medicines), (20) (is professionally, physically, or mentally incompetent).

ORDER

It is therefore, this _____ day of April, 1999, by the State Pharmacy Board,

ORDERED, that pursuant to the authority granted the Board by Md. Code Ann., State Gov't §10-226 (c) (2) (1995), the license of the Respondent, **Behrooz Goodarzi, P.D.** (No. 10724), to practice pharmacy in the State of Maryland, be and is hereby **SUMMARILY**

SUSPENDED; and be it further

ORDERED, upon presentation of this Order for summary suspension, Respondent shall immediately deliver to the Board, through the Board's executive director or its designee, the display, renewal certificate, and wallet-sized license to practice pharmacy previously issued by the Board; and be it further

ORDERED, that a show cause hearing shall be scheduled on **Tuesday, April 13, 1999, at 1:30 p.m.**, at 4201 Patterson Avenue, Baltimore, Maryland 21215 at which the Respondent will be given an opportunity to be heard on the issues limited to those raised in this Order, that is, regarding the Respondent's fitness to practice pharmacy and the danger to the public. Any such hearing will be held before the Board or its designee.

NOTICE OF HEARING

A full evidentiary hearing will be scheduled before the Board at 4201 Patterson Avenue, Baltimore, Maryland 21215 upon Respondent's written request. Any such hearing will be scheduled to be heard by the Board within thirty (30) days of receipt of Respondent's written request therefor.

_____ _____

Date

W. Irving Lottier, Jr., P.D.
Secretary, Board of Pharmacy

EXHIBIT A

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-24-88 SHEET 2 OF 8

Pharmacy Name Mcleod Pharmacy

ITEM No.	LIST OF OBSERVATIONS
#9	222 forms — McKesson Drug Co
#7	Invoices Sche III - V invoices
Inventory	Percocet — Generic 208 — Brand 151
	Ritalin 10 mg — 335 — 265
	Ritalin 5 mg — 688
#13	Be sure schedule II drugs are dispensed or locked in drawer — presently kept in plastic bag on floor of pharmacy
#18	Don't cover exp. date or lot # with price stickers
#6	Biennial Inventory is not available in pharmacy (was sent to Drug Control last year and did not keep copy in pharmacy ?)
#36	Generic substit. mfg not recorded on Rx
#16+17	See list of outdates. Owner pharmacist also removed over 100 drugs from shelves - more are on shelves. Must be removed.

Received by [signature] Inspected by Cathleen S Lutz

DHMH-1344

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-24-98 SHEET 3 OF 8

Pharmacy Name: Mellwood

ITEM No.	LIST OF OBSERVATIONS
	Outdates:
	Methyldopa and Hydrochlorothiazide Tablets 500mg /30mg (Zenith Goldline) 5/1988,
	Aldoril 15 9/87, Bromfed 6/97, Apresazide 50/50 2/94,
	Bromfed-PD (empty bottle) 9/97, Altace 10mg 2/98,
	Aldoril 25, 1/98, Axid Jan 1, 1994, Adalat CC 30mg – label
	pasted on bottle no lot # or exp. date, Altace 2/98,
	~~Methyldopa 500mg~~ Disulfiram 2/99, Aricept 5mg – bottle with
	label cut out and pasted on bottle – no exp date or lot #,
	Spironolactone and HCTZ (URL) 25/25mg 3/94, Spironolactone and HCTZ (URL) 25/25 11/
	Hydralazine HCl + HCTZ 25/25 (Zenith Goldline) Jan 1992
	Aldomet 125mg 4/89, Altace 2.5mg 1/98, Anafranil 25mg 1/96,
	Benemid 0.5g (empty bottle) 5/89, Daypro 150mg relabeled with
	cut off label pasted on, no lot # or exp date, Bumex 2mg empty 11/1/95
	Bumetanide 0.5mg 10/1/96, Bumex 0.5mg 6/1/96, Bumetanide 0. 10/1/9
	Clinoril 150mg 1/94, Comhist LA 2/88, Cycrin – no exp date or
	lot #, bottle relabeled with cut off label, ColBenemid 12/97,
	Empirin with Codeine #4 12/95, Plendil 5mg 4/97, Plendil 6/9
	Doral 10/96, Dolobid 9/96, Plendil 2.5mg label pasted on bottle
	no lot # or exp date, Plendil – repackaged with pasted label in Rx vial
	Nicotine Exp. 11/94, Lortab Elixir repackaged with pasted label no lot #
	Nicotine Exp 11/94 empty bottle, ~~Lortab Elixir 1/?~~,
	Naldecon Ped Syrup 12/97, Prednisone Syrup empty bottle in de
	Saliva Substitute (Roxane) 3/94, Sulfoxyl Acne Lotion 7/90
	Dermatop 2/96, Halotex Cream 1.0% 1/94, Cyclocort Cr 12/9
	Cleocin-T / Clindamycin Sol. 1% 11/97,

Received by [signature] Inspected by [signature]

DHMH-1344

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-24-98 SHEET 4 OF 8

Pharmacy Name Mellwood

ITEM No.	LIST OF OBSERVATIONS
	Zorprin 500g (Aspirin) repack with label pasted over another one no exp date or lot #, Zarontin 1/94, Suprax 10/97, Vantin Oppin 50mg/5ml 12/96, Vantin 100mg/5ml 2/98, Cephradine 250g Liquid 6/1/95 6/98 Zovirax 800g 9/96, Zyloprim 300g 3/97, Fulvicin PG 330 Prenate U.F Zenate 6/95, Flexin 300mg (empty bottle) 5/98, Zyloprim 300g 3/9 Keflex 250g 6/1/95, Zinc 2.5g 8/98, Loxitid 200g/5ml 4/1/9 Flagyl 500g 1/97, Zorprin Roots Skin ASA 300g 3/91, Diclofenac Oral susp 9/98, Dyazyn Oral Liq 12/97, Zinc 5g 12/98, Trandate 100g 3/93, Hydroxyzine Pamoate no exp. date or lot # Hydroxyzine Pamoate 25g (Zenith) 12/95, Diazepam 2g (Zenith) 10/9 Urinary Antispas Tablets (Alpha Cyn) Nitro Mason's Order #21440 9/27/94 exp Nov 95, Vicon Forte 3/99, ~~Trandate 300g~~ Uripas Jan 31, 199 Zenith Clorazepate 7.5g (Top Rx 3/16/98 613422) same a Transvan 5/98, Clorazepate 3.75g 9/95, Choline Mg 500g 5/96 Flagyl 375 mg 1/99 (unit dose x 8 capsules) Loxitid 200g Jan 1, 1999, Ampicillin for Oral Susp 125g 15ml w/c 12/ Ampicillin 250g Capsules (Warner Chilcott) 7/98, Loxitid 200g Jan 1, 1999, Sulfamethoxazole and Trimethoprim 400/80 (Schein) 2/97 Cefzil - tablet repackaged in Rx vial - no lot # or exp dates (empty bottle) Clevrin 150g Capsules 4/95, Dynaban 250g Sept 1, 1997 Loxitid 400g Aug 1, 1998, Augment 125g unit dose chewable tablet 1/92 Augmentin 250g unit dose chewable packaged tablet 8/98, Augmentin 200g chewable UD, Horizon UroPak Sample (6 tabs) No exp date - date of packaging marked 8-1-95, Cefaclor 500g repackaged Rx vial - No lot # or exp. date

Received by [signature] Inspected by Catherine J Fry

DHMH-1344

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-24-95

SHEET 5 OF 8

Pharmacy Name: Mattwood [illegible]

ITEM No.

LIST OF OBSERVATIONS

~~Stelazine 1mg exp 3/95 (no lot # repackaged)~~, Geneva
~~Sodium Chloride 1gram 7/1/1988~~, Trifluoperazine 2mg 11/96,
Synthroid 200 mcg repackaged with pasted on label in Rx vial with
no lot # or exp date, Cardec TR (Boldine) labeled with
Rondec TR tag on it also 3/95, Tuss-tan 4/97 labeled with
Repertuss written on regular label, Doxepin Mylan 10/96, ~~Soma Cpd~~ 1/87
Rifadin 300mg 9/98, Sectral 400mg exp date + lot # covered -
Trifluoperazine Geneva 5mg 6/98, Regulin 200mg 9/98,
Slo-bid 100mg 4/97, Methocarbamol and ASA 400mg/325mg Zenith 8/95
Slo-bid 100mg 12/96, Semprex-D capsules - label pasted on - no lot #
Reserpine, Hydralazine, HTZ 0.1mg/25/15mg (Danbury) 3/94, Tri-Stann Duramed 5/9
Trifluoperazine Mylan 10mg 6/93, Brevoxyl gel Stiefel 9/95,
Kenalog 0.1% cream 8/95, ~~Aristocort Triamcinolone cream~~ [illegible]
Persa-Gel 10% 12/92, / Meclan Cream 1% 11/94,
~~Mycolog II~~ Zyrtec liquid rebottled in soda bottle with label pasted on
Ortho-Novum 1/50 28 day 12/94, Modicon 28 4/97
Demulen 1/50-28 3/96, Ortho Cyclen - samples, Loestrin Fe 12/98
Ovral-28, 1/97, Pilopine HS Gel 9/97,
Cortisporin Suspension Otic 10/98, Coly-Mycin S Otic 9/97, Rum-K Sample 6/98
Tussi-Organidin DM 2/87 (empty bottle), Dimetane DC cough 10/97
~~Dopan~~ Barre Elixir 8/96, Ambenyl Cough Syrup 1/88, Alkapent Syrup 7/9
Bromfed DM Cough Syrup - labeled with handwritten auxiliary label Dimetane-D.
(empty bottle) 6/94, Bromanyl Barre Cough Syrup 7/98, Rondec Syrup 2/11
Pediapred 1/95, Tussar SF (labeled with Robitussin DAC also on it) 8/96
~~Dophen~~ Barre 6/96, Tussar-2 (10 ml in bottle) 9/93, Triacin-C Cough Syrup 12/96 [illegible]

Received by: [signature]   Inspected by: [signature]

~~Dophen~~-C Liquid 2/87, ~~Dophen~~-C liquid 2/87

DHMH-1344

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-24-99 SHEET 6 OF 8

Pharmacy Name: Mellwood

ITEM No.	LIST OF OBSERVATIONS
	bottle of unlabeled capsules in box with Inderide LA 80/50mg
	Propranolol + HCTZ 80mg/25 (Mylan) 2/92
	Propranolol + HCTZ 80/25mg 2/92 (another bottle)
	Inderal LA 160mg 3/92, Inderal LA 60mg 7/97
	Inderal 80mg (Ayerst) 11/88, Inderal LA 60mg 8/86
	Mellaril 10mg 7/94, Isorbide (ER) 40mg 11/94
	Lopressor 100mg 4/98, Materna (pre-natal vit) 11/97
	Mestinon 10/1/97, Isordil 30mg 3/94, Meclofenamate 50mg 2/92
	Mellaril 15mg tablet July 88, Moduretic 50mg 7/97
	Lotrel 2.5/10 10/98, Thiothixene cap 5mg 10/98, Naproxen 10/95
	Thiothixene 1mg 1/98, Rufen 600mg 9/1/93,
	Quinidex 300mg repackage 3/94 exp.) Pyridium Plus 11/89
	Ami-Dem (SA) same as Nalden Jan 96(?)
	Erythromycin Susp. 400mg/5ml 9/98, Erythromycin Susp 10/98
	Minipress 2mg May 95, Amiloride HCl 5/50mg 3/98
	Midamor 5mg 6/92, Moduretic 5-50 6/96, Plaquenil 200mg 5/97 (empty bottle)
	Prerridone 250mg 9/95, Minoxidil 10mg 5/90,
	Minoxidil 2.5mg 8/95, Polaramine 8/95, Poly-histine D 2/99
	Thiothixene 2mg 2/98, Prandin 0.5mg ~~sample~~ bottle should
	only have 12 tablets — has over 100 tablets in it exp. 1/2000
	Prelu-2 105mg 7/95, Precose 100mg 8/97, Phenergan 12.5mg Supp 12/98
	Dipyridamole tablet 75mg 9/97, Proventil 4mg 12/95
	Prochlorperazine Supp 25mg 12/97, Provera 5mg 9/98, Precose 50mg 1/98
	Precose 25mg 2/99, Propranolol 10mg 6/97, Polaramine repetabs 6mg 10/87
	Premarin 2.5mg 3/97

Received by [signature] Inspected by [signature]

DHMH-1344

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-24-99

Pharmacy Name: Mellwood

ITEM No. | LIST OF OBSERVATIONS

Temazepam 15mg 11-98, Synthroid 150mg 5/98
Guanfacine tablets 1mg 1/99, Compazine 25mg 9/30/92
Floxin 400mg 6/96, Col-Probenecid (URL) 10/98
Benztropine 0.5mg Schein 11/97, Codimal LA 10/96
Benztropine 0.5mg Schein 10/98, Codimal LA Ext. R repackaged in Rx vial
no exp. date or lot #, Compazine 5mg 8/11/97, DiaBeta 2.5mg 7/97
Dyrenium capsules 1/31/95, Bottle of approx over 1000 ~~tablets~~ repacked
with pasted on BuSpar 15mg label lot # MK0894E, exp 1 Nov 99
(Pharmacist explained he repackaged a lot of small bottles he had
purchased from a store) Buspar 5mg 2/99
Prenate Ultra ~~samples~~ exp 11/98, Brontex 6/95
Glucotrol 10mg 8/98, ~~Buspar 5mg~~ Trihexyphenidyl HCl 2mg Schein 3/9
Calan SR 180 SR 10/98, Triamcinolone 4mg Jan 90,
Amoxapine 100mg June 97, Calan 80mg tablets 9-88, Verapamil 10/98
Ornade Spansule expires 1994, orange and multicolored capsule
with Ornade written on it, Butazolidin 100mg 3/93
Phenylbutazone Barr lab 100mg 4/92 (orange tablet), PBZ-SR 100mg 11/95
Tolbutamide 500mg 1/98, ~~Isordil 30mg~~ Anabolic - Irwin, Co
~~Isordil~~ Glycerol 30mg NDC # 55053-250-05 Econolab
Ted. Cotton 5/96, (x 2 bottles); Librium 5mg - repackaged with pasted on
label with 11-1-96 exp date (yellow-green name on capsule)
Chlordiazepoxide HCl 10mg 8/98, Levsinex Timecaps 12/97
Levothroid Forest 100mcg 10/94, Chlordiazepoxide 25mg 9/97
Levothroid Forest 150mcg 11/94, Chlordiazepoxide + Amitriptyline 10/25 7/95
Lorcet 10/650 10/98, ~~Ismo~~ (~~Isordil~~) 20mg 9/98,

Received by: [signature] Inspected by: [signature]

DHMH-1344

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTA. .YGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-24-98 SHEET 8 OF 8

Pharmacy Name Mellwood

ITEM No.	LIST OF OBSERVATIONS
	Cefaclor 250mg (Schein) 8/98, Ceclor 250mg 2/1/98
	Pediazole 5ml (for oral susp) June 1, 1998, Pediazole (Susp) June 1, '98
	PCE 333mg Feb 1, 1994, Beepen-VK (Smith Kline Beecham) for oral soln 10/97
	Pen VK oral sol. (Beecham) 4/93, Maxaquin 400mg (Searle)
	Exp 4/95, Neomycin Sulfate 0.5 Gm Biocraft 12/1/91,
	Minocin 50mg 11/92, Famvir 500mg 11/98, Diflucan Jan 1, 19
	Pen VK oral sol. 125mg 4/93, Pen VK 125mg/5ml 200ml 10/97, ~~PCE~~ Elavil 75
	1/95, Minocin 50mg 11/92, Neomycin Sulfate 0.5Gm tablet 12/1/91
	Synthroid 300mcg 5/98, Famvir 500mg 11/98, Doxepin 25mg 12/9
	Tagamet 400mg 10/31/97, Elavil 50mg 6/98, Levoxyl 12/97
	Tagamet 800mg 6/30/96, Tavist 1/96,
	Tenormin 100mg 11/98, Doxepin 25mg 11/98, DHC plus 5/95
	Amitriptyline 100mg 1/98, Tavist-D 7/94, Theo-Dur 7/90 200mg
	Diflucan 100mg Jan 1, 1997, Theo-Dur 200mg 4/92,
	Maxaquin 400mg 4/95, Tigan 250mg caps 8/97,
	Thorazine 50mg 2/28/89, Synalgos-DC 1/97, Tagamet 300mg 8/31
	Temazepam 15mg 11/98, Temazepam 15mg 11/98
	Amitriptyline 50 tablet 6/96, Dilantin with ½ gr phen 7/88,
	Restoril 15mg 7/98, Tenoretic 100 6/93, Dilantin 30mg 7/95
	Reglan 10mg 10/96, Risperdal 3mg 12/97, Doxepin 10mg 2/95
	Amantadine 100mg 8/95, Tofranil 25mg 10/93,
	Symmetrel 100mg - empty bottle of 8/89 exp date, Imipramine 10mg 4/98
	Cimetidine 300mg tablet 5/96, Restoril 30mg Jan/97
	Levoxyl 112 mcg 9/98, Theophylline SR 450mg 4/97
	Tenoretic exp 6/96 no lot # repackaged, Sinemet 25-250 4/98

Received by [signature] Inspected by [signature]

DHMH-1344

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-30-99

SHEET 1 OF 3

Pharmacy Name Melrose

ITEM No.	LIST OF OBSERVATIONS
	Atropine 50z Opth. Sol 1% exp 12/96
	Atropine Sulf. opth Oint 1% exp 3/98
	Terak 3.5G Akorn opth oint. Feb 1, 1998
	Glaucide 0.1% opth Sol 6/96
	Bethanechol 50z (Schein) 7/97, Bethanechol 25z (Schein) 3/98
	Tylenol with Codein #4 8/97, Bactrim DS 9/96
	Bactrim DS 9/96, Bethanechol 10z tablets (Schein) 11/98
	Vantin 100z 3/99, Risperdal 2mg 2/99,
	Temazepam Capsules 15z 11/98, Urinary Antiseptic Alphagen Nov. 95
	Zantac 150z No exp date or lot #
	Metaproterenol Sulfate pr Oral Inh. 0.4% 6/98
	Progesterone Powder 9/97, Testosterone Powder CIII 11/96
	Folic Acid 1z tablets (Schein) 3/98, Coumadin 4mg 12/94
	Cytotec 100mcg 1/98, Cytomel 1/97, Cylert 37.5 Dec 1, 199
	Cytotec 200mcg 11/94, Coumadin 7½mg 2/98
	Salagen in Expectus 11/92, Lindane Shampoo 1% 7/97
	Docusate Syrup exp 2/91, Novahistine Expectus 2/88
	#127382 3-29-99 127385 3-26-99 127200 3/22
	127000 3-12-99

Received by _____ Inspected by _____

DHMH-1344

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

TE 3-30-98

Pharmacy Name: Malwood

ITEM No.	LIST OF OBSERVATIONS
	Cardiazem 180mg repackaged with label with no lot # or exp date
	Label cut from physician's sample, Xanax 2mg 1/95
	Android 25mg ICN 7/96
	Procardia XL 60mg GITS lot # 15598 exp 12/1/98 pfizer
	Repacked by CVS Woonsocket RI 02895 item 671875
	NDC 0069-2660-66
	Danocrine 200mg 2/95, Imipramine 25mg 7/98
	Dexamethasone 2mg tablets unit dose package with 24-188L Aug/96
	C556XN 09 Malwood
	Deconsal II 10/97, Rx 045628 for Decadron on shelf
	exp 4/3/91
	Deconsal Sprinkle 4/94 (Adams Lab)
	Lasix 80mg tab 3/89, Claritin RediTabs samples 7 pks of 4/10
	Cortenema 9/98, Hydralazine 10mg Zenith 12/87,
	Cotazym 11/97, Cardiazem SR 60mg 9/97
	Unlabeled Rx vial - blue & yellow capsules
	Asendin 50mg 3/92, Isoxsuprine Tablets Rugby 10mg
	Diabeta 5mg 10/98, Verelan 240mg 11/97
	Rezulin 200mg 2/99, Dura-Vent/DA 1/99
	Cardiazem 90mg 6/94 (green tablets)
	Zestril 10mg - repackaged National PharmPak Services Inc
	Lot # CRH700 Zanesville, Ohio 43701
	L 23250198
	exp 05/00

Received by ________ Inspected by ________

DHMH-1344

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

ATE 3-30-99

Pharmacy Name Medwood

ITEM No.	LIST OF OBSERVATIONS
	Normodyne 200 mg pink tabs repack by Drug Distributors, Inc. Buffton IN 46714 0085-0752-04 exp March 2000 Lot FRHR778 Schering 6505-01-209-1212
	Cyproheptadine Tablets 4mg (Schein) 9-96, Donocrine 200mg 11/94
	Dipyridamole 25mg 12/90 (Unnamed) white coated tabs #25
	Diethylstilbestrol tabs (Lilly) 5mg May 1, 1994,
	Darvon-N 100 mg 8/1/93, D.A. Chewable Tablets 9/94
	Catapres 0.3mg Jan 94, Propoxyphene Cpd 65 (Lemon) 2/97
	Phenergan 12.5mg 4/96 orange tablet #19, Cyproheptadine 4mg 12/97 Schein
	Hytrin 5mg Dec 1, 1998, Hytrin 10mg Feb 1, 1999, Poly-histine D 2/9 3/9
	Calan SR 240 mg, repackaged with label with exp 3/97, Neo Gram 500mg
	Nitrostat Susp 6/97, Biaxin 500mg March 1, 1995,
	Amaryl tablet 2mg 1/99, Carafate 1Gm March 98
	Trental 400mg 2/99, Amaryl 1/99, Ten-K 10 meq 11/91
	Multivit-Folic 500mg 4/95 (Copley Pharm. Inc.)
	Furosemide Tablets USP 40mg Unit Dose by Britton use only
	210-7555 UDL exp 3/00
	D855A Lot SC551
	13 2 Medwood HX1 N5107507301

Received by _____ Inspected by _____

DHMH-1344